Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter A Ljubenkov

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
Acta Neuropathologica|September 19, 2023
Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumabLawren VandeVrede, Renaud La Joie, Sheena Horiki, et al.
Neurology. Clinical Practice|June 30, 2025
Changes of a Cerebral Cavernous Malformation Associated With Lecanemab Therapy in a Patient With Alzheimer DiseaseNicholas U Schwartz, Connor D Dietz, Igor Prufer Araújo, et al.
Frontiers in Neurology|October 18, 2019
Peripheral Innate Immune Activation Correlates With Disease Severity in <i>GRN</i> HaploinsufficiencyPeter A Ljubenkov, Zachary Miller, Paige Mumford, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 28, 2024
Clinicopathological correlation of cerebrospinal fluid alpha-synuclein seed amplification assay in a behavioral neurology autopsy cohortNiyatee Samudra, D Luke Fischer, Steven Lenio, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 24, 2025
BiomarkersRowan Saloner, Joshua Downer, Argentina Lario Lago, et al.
JAMA Neurology|December 21, 2019
Association of Cognitive and Behavioral Features Between Adults With Tuberous Sclerosis and Frontotemporal DementiaAndy J Liu, Adam M Staffaroni, Julio C Rojas-Martinez, et al.
Movement Disorders Clinical Practice|May 7, 2020
Open-Label Phase 1 Futility Studies of Salsalate and Young Plasma in Progressive Supranuclear PalsyLawren VandeVrede, Marian L Dale, Scott Fields, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|January 31, 2025
Clinical and neuropathological associations of plasma Aβ<sub>42</sub>/Aβ<sub>40</sub>, p-tau217 and neurofilament light in sporadic frontotemporal dementia spectrum disordersBinita Rajbanshi, Igor Prufer Q C Araujo, Lawren VandeVrede, et al.
Annals of Clinical and Translational Neurology|October 24, 2018
Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectoryPeter A Ljubenkov, Adam M Staffaroni, Julio C Rojas, et al.
Brain : a Journal of Neurology|January 31, 2019
Longitudinal multimodal imaging and clinical endpoints for frontotemporal dementia clinical trialsAdam M Staffaroni, Peter A Ljubenkov, John Kornak, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Acta Neuropathologica|September 19, 2023
Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumabLawren VandeVrede, Renaud La Joie, Sheena Horiki, et al.
Neurology. Clinical Practice|June 30, 2025
Changes of a Cerebral Cavernous Malformation Associated With Lecanemab Therapy in a Patient With Alzheimer DiseaseNicholas U Schwartz, Connor D Dietz, Igor Prufer Araújo, et al.
Frontiers in Neurology|October 18, 2019
Peripheral Innate Immune Activation Correlates With Disease Severity in <i>GRN</i> HaploinsufficiencyPeter A Ljubenkov, Zachary Miller, Paige Mumford, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 28, 2024
Clinicopathological correlation of cerebrospinal fluid alpha-synuclein seed amplification assay in a behavioral neurology autopsy cohortNiyatee Samudra, D Luke Fischer, Steven Lenio, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 24, 2025
BiomarkersRowan Saloner, Joshua Downer, Argentina Lario Lago, et al.
JAMA Neurology|December 21, 2019
Association of Cognitive and Behavioral Features Between Adults With Tuberous Sclerosis and Frontotemporal DementiaAndy J Liu, Adam M Staffaroni, Julio C Rojas-Martinez, et al.
Movement Disorders Clinical Practice|May 7, 2020
Open-Label Phase 1 Futility Studies of Salsalate and Young Plasma in Progressive Supranuclear PalsyLawren VandeVrede, Marian L Dale, Scott Fields, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|January 31, 2025
Clinical and neuropathological associations of plasma Aβ<sub>42</sub>/Aβ<sub>40</sub>, p-tau217 and neurofilament light in sporadic frontotemporal dementia spectrum disordersBinita Rajbanshi, Igor Prufer Q C Araujo, Lawren VandeVrede, et al.
Annals of Clinical and Translational Neurology|October 24, 2018
Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectoryPeter A Ljubenkov, Adam M Staffaroni, Julio C Rojas, et al.
Brain : a Journal of Neurology|January 31, 2019
Longitudinal multimodal imaging and clinical endpoints for frontotemporal dementia clinical trialsAdam M Staffaroni, Peter A Ljubenkov, John Kornak, et al.
Pageof 4